Price T Rowe Associates Inc. MD Has $500.69 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Price T Rowe Associates Inc. MD decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,872,389 shares of the biopharmaceutical company’s stock after selling 2,084,603 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 0.33% of Pfizer worth $500,685,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Passumpsic Savings Bank grew its holdings in Pfizer by 8.4% during the third quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company’s stock valued at $743,000 after purchasing an additional 1,998 shares during the last quarter. Virtu Financial LLC bought a new position in Pfizer in the 3rd quarter worth $1,499,000. Westside Investment Management Inc. lifted its position in Pfizer by 7.7% during the 3rd quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 1,004 shares during the last quarter. Diamant Asset Management Inc. boosted its holdings in Pfizer by 8.4% during the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 660 shares during the period. Finally, Morse Asset Management Inc acquired a new stake in shares of Pfizer in the third quarter valued at about $2,649,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on PFE shares. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group lowered their price target on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday, April 8th. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $29.57.

Pfizer Stock Up 1.8 %

Shares of PFE opened at $22.80 on Friday. The firm has a market capitalization of $129.31 billion, a price-to-earnings ratio of 16.17, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business’s fifty day moving average price is $24.63 and its two-hundred day moving average price is $26.01.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the company earned $0.10 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.54%. Pfizer’s dividend payout ratio is currently 121.99%.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.